These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29548736)

  • 1. Combination therapies and intra-tumoral competition: Insights from mathematical modeling.
    Piretto E; Delitala M; Ferraro M
    J Theor Biol; 2018 Jun; 446():149-159. PubMed ID: 29548736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations.
    de Pillis LG; Gu W; Radunskaya AE
    J Theor Biol; 2006 Feb; 238(4):841-62. PubMed ID: 16153659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy.
    Serre R; Benzekry S; Padovani L; Meille C; André N; Ciccolini J; Barlesi F; Muracciole X; Barbolosi D
    Cancer Res; 2016 Sep; 76(17):4931-40. PubMed ID: 27302167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation.
    Chisholm RH; Lorenzi T; Clairambault J
    Biochim Biophys Acta; 2016 Nov; 1860(11 Pt B):2627-45. PubMed ID: 27339473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An extended mathematical model of tumor growth and its interaction with the immune system, to be used for developing an optimized immunotherapy treatment protocol.
    Qomlaqi M; Bahrami F; Ajami M; Hajati J
    Math Biosci; 2017 Oct; 292():1-9. PubMed ID: 28713023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mathematical Modelling and Analysis of the Tumor Treatment Regimens with Pulsed Immunotherapy and Chemotherapy.
    Pang L; Shen L; Zhao Z
    Comput Math Methods Med; 2016; 2016():6260474. PubMed ID: 26997972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the effects of space structure and combination therapies on phenotypic heterogeneity and drug resistance in solid tumors.
    Lorz A; Lorenzi T; Clairambault J; Escargueil A; Perthame B
    Bull Math Biol; 2015 Jan; 77(1):1-22. PubMed ID: 25480478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mathematical modeling of combined therapies for treating tumor drug resistance.
    Bao K; Liang G; Tian T; Zhang X
    Math Biosci; 2024 May; 371():109170. PubMed ID: 38467302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.
    Baxevanis CN; Perez SA; Papamichail M
    Cancer Immunol Immunother; 2009 Mar; 58(3):317-24. PubMed ID: 18704409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery.
    Goldberg EP; Hadba AR; Almond BA; Marotta JS
    J Pharm Pharmacol; 2002 Feb; 54(2):159-80. PubMed ID: 11848280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addressing current challenges in cancer immunotherapy with mathematical and computational modelling.
    Konstorum A; Vella AT; Adler AJ; Laubenbacher RC
    J R Soc Interface; 2017 Jun; 14(131):. PubMed ID: 28659410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer.
    Hughes PE; Caenepeel S; Wu LC
    Trends Immunol; 2016 Jul; 37(7):462-476. PubMed ID: 27216414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
    Madden DL
    Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metronomic chemotherapy and immunotherapy in cancer treatment.
    Chen YL; Chang MC; Cheng WF
    Cancer Lett; 2017 Aug; 400():282-292. PubMed ID: 28189534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of chemotherapy using oncolytic virotherapy: Mathematical and optimal control analysis.
    Malinzi J; Ouifki R; Eladdadi A; Torres DFM; White JKA
    Math Biosci Eng; 2018 Dec; 15(6):1435-1463. PubMed ID: 30418793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells?
    Zhang L; Dermawan KT; Jin ML; Xiong SD; Chu YW
    Med Hypotheses; 2008 Nov; 71(5):802-4. PubMed ID: 18691831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adapting conventional cancer treatment for immunotherapy.
    Qiao J; Liu Z; Fu YX
    J Mol Med (Berl); 2016 May; 94(5):489-95. PubMed ID: 26910191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mixed immunotherapy and chemotherapy of tumors: feedback design and model updating schemes.
    Chareyron S; Alamir M
    J Theor Biol; 2009 Jun; 258(3):444-54. PubMed ID: 18655792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On probabilistic certification of combined cancer therapies using strongly uncertain models.
    Alamir M
    J Theor Biol; 2015 Nov; 384():59-69. PubMed ID: 26300070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gut microbiota and efficacy of cancer therapies].
    Vétizou M; Daillère R; Zitvogel L
    Biol Aujourdhui; 2017; 211(1):51-67. PubMed ID: 28682227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.